Methods and kits for diagnosing kawasaki disease and methods for treating kawasaki disease
AssigneeChang Gung Memorial Hospital, Kaohsiung
InventorsYing-Hsien Huang, Ho-Chang Kuo
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods that use novel biomarkers for diagnosing and/or treating Kawasaki diseases. The novel biomarkers of the invention show altered cytosine methylations state of certain CpG loci in subject with Kawasaki Disease relative to subject without Kawasaki diseases. Also provided are kits comprising at least one primer or reagent specific for the altered cytosine methylation state of certain CpG loci to detect Kawasaki Disease.
Claims16
A method for treating Kawasaki disease (KD) in a subject in need thereof, comprising the steps of:
- (a) obtaining a sample from the subject, wherein the subject exhibits one or more symptoms of KD or is at risk of developing KD;
- (b) measuring the cytosine methylation state of at least one CpG dinucleotide selected from cg23677000, cg04085447, cg17907567, cg26283059 or cg27273033 from the sample of the subject;
- (c) identifying the subject as having KD or at risk of developing KD by identifying that at least one CpG dinucleotide measured in step (b) is lower compared to the corresponding CpG in a control or a KD-free sample;
- and
- (d) administering a therapeutic agent for KD to the subject having KD or at risk of developing KD.
A method for reducing coronary artery disease in a subject suspected of having Kawasaki disease (KD), comprising:
- (a) obtaining a sample from the subject, wherein the subject exhibits one or more symptoms of KD or is at risk of developing KD;
- (b) measuring the cytosine methylation state of at least one CpG dinucleotide selected from cg23677000, cg04085447, cg17907567, cg26283059 or cg27273033 from the sample of the subject;
- (c) identifying the subject as having KD or at risk of developing KD by identifying that at least one CpG dinucleotide measured in step (b) is lower compared to the corresponding CpG in a control or a KD-free sample;
- and
- (d) administering a therapeutic agent for KD to the subject having KD or at risk of developing KD.
Dependencies are inferred from the claim text.